Table 3 Correlation between clinicopathological features and each intrinsic subtype in 55 patients with recurrence after surgery
Parameters | Intrinsic subtype | p-value | |||
|---|---|---|---|---|---|
Luminal (n = 23) | Luminal-HER2 (n = 3) | HER2-enriched (n = 9) | TNBC (n = 20) | ||
Age at operation | |||||
 ≤ 56 | 13 (56.5%) | 2 (66.7%) | 5 (55.6%) | 11 (55.0%) |  |
 > 56 | 10 (43.5%) | 1 (33.3%) | 4 (44.4%) | 9 (45.0%) | 0.985 |
Menopause | |||||
 Pre- | 10 (43.5%) | 2 (66.7%) | 4 (44.4%) | 8 (40.0%) |  |
 Post- | 13 (56.5%) | 1 (33.3%) | 5 (55.6%) | 12 (60.0%) | 0.860 |
Tumor size (cm) | |||||
 ≤ 2 | 2 (8.7%) | 0 (0.0%) | 1 (11.1%) | 2 (10.0%) |  |
 > 2 | 21 (91.3%) | 3 (100.0%) | 8 (88.9%) | 18 (90.0%) | 0.888 |
Lymph node status | |||||
 Negative | 2 (8.7%) | 1 (33.3%) | 2 (22.2%) | 5 (25.0%) |  |
 Positive | 21 (91.3%) | 2 (66.7%) | 7 (77.8%) | 15 (75.0%) | 0.437 |
Nuclear grade | |||||
 1, 2 | 18 (78.3%) | 3 (100.0%) | 8 (88.9%) | 16 (80.0%) |  |
 3 | 5 (21.7%) | 0 (0.0%) | 1 (11.1%) | 4 (20.0%) | 0.620 |
Ki67 (%) | |||||
 ≤ 14 | 11 (47.8%) | 3 (100.0%) | 4 (44.4%) | 8 (40.0%) |  |
 > 14 | 12 (52.2%) | 0 (0.0%) | 5 (55.6%) | 12 (60.0%) | 0.175 |
Pathological response | |||||
 Non-pCR | 17 (73.9%) | 3 (100.0%) | 5 (55.6%) | 16 (80.0%) |  |
 pCR | 6 (26.1%) | 0 (0.0%) | 4 (44.4%) | 4 (20.0%) | 0.306 |
Metastatic site | |||||
 Local/bone | 16 (69.6%) | 2 (66.7%) | 5 (55.6%) | 12 (60.0%) |  |
 Distant | 7 (30.4%) | 1 (33.3%) | 4 (44.4%) | 8 (40.0%) | 0.866 |
Relapse-free survival (years) | |||||
 < 2 | 13 (56.5%) | 1 (33.3%) | 5 (55.6%) | 16 (80.0%) |  |
 ≥ 2 | 10 (43.5%) | 2 (66.7%) | 4 (44.4%) | 4 (20.0%) | 0.220 |